Zomepirac is an orally effective non-steroidal anti-inflammatory drug (NSAID) that has antipyretic actions. It was developed by McNeil Pharmaceutical and approved by the FDA in 1980 and sold as the sodium salt, zomepirac sodium, under the brand name Zomax. Due to its clinical effectiveness, it was preferred by doctors in many situations and obtained a large share of the analgesics market; however, it was subsequently withdrawn in March 1983 due to its tendency to cause serious anaphylaxis in an unpredictable subset of the patient population.

CAS：33369-31-2
中文别名：
英文别名：Zomax;5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetic acid;Zomepirac [INN:BAN];EINECS 251-474-2;ZOMEPIRAC SODIUM;5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid;[3H]-Zomepirac;5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-acetic acid;Zomepiracum [INN-Latin];[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]acetic acid;Zomepiracum;
分子式：C15H14ClNO3
分子量：291.73
精确质量：291.066
Psa：59.3
Logp：2.845

UNII：822G987U9J

密度：1.28g/cm3
沸点：470.8ºC at 760mmHg
闪点：238.5ºC
折射率：1.595

海关编码：2933990090